AstraZeneca’s Iressa Faces Generic Competition In China

China pharma

AstraZeneca’s Iressa, which is used to treat non-small cell lung cancer (NSCLC), still has patent protection in the United States. But the drug is now facing generic competition in China, from local Chinese firm Qilu Pharmaceutical. Qilu’s generic version of Iressa is called Yiruike. Qilu received approval from the Chinese Food and Drug Administration to launch a generic after AstraZeneca’s patent expired last April.

Read the source article at The Pharma Letter

About the Author

Related Posts

Leave a Reply